New Wave Biotech is a London-based startup founded in 2022 that offers an AI-powered Bioprocess Foresight platform to simulate bioprocesses and predict quantified output, costs, and sustainability impact. The platform improves over time by learning from empirical data and is designed to help biomanufacturing teams design smarter, commercialise quicker, and scale greener. The company targets applications across alternative proteins, biochemicals, and biomaterials to reduce emissions and transform supply chains. New Wave plans to use its latest funding to expand its team, explore new markets and customers, and invest in product and technology development. The startup positions its software as a way to shorten long R&D timelines and reduce the high costs of experiments that hinder scale-up. Financially, it has raised €1.2 million in its latest round of equity and grant funding and has previously received grant awards from Innovate UK and investment from Big Idea Ventures. New Wave Biotech builds solutions aimed at helping alternative-protein companies scale quickly, cheaply, and sustainably. The company was selected to join the Big Idea Ventures Accelerator and to join a community of pioneering alt-protein founders. As part of the program it receives pre-seed funding from Big Idea Ventures and is one of the first investments made through Big Idea Ventures' newly launched New Protein Fund II. New Wave Biotech says BIV's expertise, network, and resources will supercharge its growth and support its mission. Through the accelerator it will gain access to Big Idea Ventures' global network and strategic partners to accelerate commercialization and scaling.

Total raised

$1M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2024